Publications by authors named "Steven B Ketchum"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

1,015,425

Total Likes

24,784

Extended Reach

3,374,835

Social Features

247
E
Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT.
Deepak L Bhatt, Ph Gabriel Steg, Michael Miller, Eliot A Brinton, Terry A Jacobson, Steven B Ketchum, Ralph T Doyle, Rebecca A Juliano, Lixia Jiao, Craig Granowitz

J Am Coll Cardiol· June 2019

Videos about Article: user user

2 3 3 47 2

View All Article and Social Media Activity
C
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.
Deepak L Bhatt, P Gabriel Steg, Michael Miller, Eliot A Brinton, Terry A Jacobson, Steven B Ketchum, Ralph T Doyle, Rebecca A Juliano, Lixia Jiao, Craig Granowitz

January 2019

Videos about Article: user user user 16

19 47 222 28 208 4

View All Article and Social Media Activity
B
Benefit of Icosapent Ethyl Across Types and Sizes of Myocardial Infarction in REDUCE-IT.
Chen Gurevitz, Deepak L Bhatt, Robert P Giugliano, Ph Gabriel Steg, Michael Miller, Steven B Ketchum

Eur J Prev Cardiol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiovascular Outcomes With Icosapent Ethyl by Baseline Low-Density Lipoprotein Cholesterol: A Secondary Analysis of the REDUCE-IT Randomized Trial.
Rahul Aggarwal, Deepak L Bhatt, Ph Gabriel Steg, Michael Miller, Eliot A Brinton, Steven B Ketchum

J Am Heart Assoc· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Icosapent ethyl following acute coronary syndrome: the REDUCE-IT trial.
Neila Sayah, Deepak L Bhatt, Michael Miller, Eliot A Brinton, Terry A Jacobson, Steven B Ketchum

Eur Heart J· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lipoprotein(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent Ethyl.
Michael Szarek, Deepak L Bhatt, Michael Miller, Eliot A Brinton, Terry A Jacobson, Steven B Ketchum

J Am Coll Cardiol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness of icosapent ethyl on first and total cardiovascular events in patients with metabolic syndrome, but without diabetes: REDUCE-IT MetSyn.
Michael Miller, Deepak L Bhatt, Eliot A Brinton, Terry A Jacobson, Philippe Gabriel Steg, Steven B Ketchum

Eur Heart J Open· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiovascular Benefits of Icosapent Ethyl in Patients With and Without Atrial Fibrillation in REDUCE-IT.
Brian Olshansky, Deepak L Bhatt, Michael Miller, Ph Gabriel Steg, Eliot A Brinton, Steven B Ketchum

J Am Heart Assoc· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial Infarction.
Prakriti Gaba, Deepak L Bhatt, Ph Gabriel Steg, Michael Miller, Eliot A Brinton, Steven B Ketchum

J Am Coll Cardiol· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE-IT PCI.
Benjamin E Peterson, Deepak L Bhatt, Ph Gabriel Steg, Michael Miller, Eliot A Brinton, Steven B Ketchum

J Am Heart Assoc· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG.
Subodh Verma, Deepak L Bhatt, Ph Gabriel Steg, Michael Miller, Eliot A Brinton, Steven B Ketchum

Circulation· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL.
Arjun Majithia, Deepak L Bhatt, Allon N Friedman, Michael Miller, Ph Gabriel Steg, Steven B Ketchum

Circulation· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT.
Prakriti Gaba, Deepak L Bhatt, Robert P Giugliano, Ph Gabriel Steg, Michael Miller, Steven B Ketchum

J Am Coll Cardiol· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
REDUCE-IT INTERIM: accumulation of data across prespecified interim analyses to final results.
Brian Olshansky, Deepak L Bhatt, Michael Miller, Ph Gabriel Steg, Eliot A Brinton, Steven B Ketchum

Eur Heart J Cardiovasc Pharmacother· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reduction in Revascularization With Icosapent Ethyl: Insights From REDUCE-IT Revascularization Analyses.
Benjamin E Peterson, Deepak L Bhatt, Ph Gabriel Steg, Michael Miller, Eliot A Brinton, Steven B Ketchum

Circulation· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response by Bhatt et al to Letter Regarding Article, "REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States".
Deepak L Bhatt, Rebecca A Juliano, Steven B Ketchum, Michael Miller

Circulation· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States.
Deepak L Bhatt, Michael Miller, Eliot A Brinton, Terry A Jacobson, Ph Gabriel Steg, Steven B Ketchum

Circulation· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial.
Deepak L Bhatt, Ph Gabriel Steg, Eliot A Brinton, Terry A Jacobson, Michael Miller, Steven B Ketchum

Clin Cardiol· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis